🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jean‐Pierre Delord

Centre de Recherches en Cancérologie de Toulouse

ORCID: 0000-0001-7305-5561

Also affiliated with Institut universitaire du cancer de Toulouse Oncopole

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study”.

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study

The Lancet. Gastroenterology & hepatology(2022)10.1016/s2468-1253(21)00382-4

N/A

2.2DataRank · unranked

73 citations

Philippe A. Cassier, Marwan Fakih, Steven Kao, Dorte Nielsen, Antoîne Italiano +17 more

Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

Cancer(2020)10.1002/cncr.33145

N/A

0.621DataRank · unranked

62 citations

Christine Alewine, Idrees Mian, Anna Spreafico, Lillian L. Siu, Carlos Gomez‐Roca +13 more

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer

The Oncologist(2023)10.1093/oncolo/oyad210

N/A

0.250DataRank · unranked

3 citations

Rona Yaeger, Jean‐Pierre Delord, Josep Tabernero, Lillian L. Siu, Michel Ducreux +9 more